NCT03822962 is a EARLY_PHASE1 clinical trial of Ibuprofen 600Mg Tablet in Nasal Sinus; Inflammation, sponsored by University of Nebraska.

Who is sponsoring NCT03822962?

NCT03822962 is sponsored by University of Nebraska.

What drugs are being tested in NCT03822962?

Interventions in NCT03822962: Ibuprofen 600Mg Tablet, Standard Regimen | Tylenol.

What condition does NCT03822962 study?

NCT03822962 studies Nasal Sinus; Inflammation, Opioid Abuse, Pain, Postoperative.

Is NCT03822962 still recruiting?

NCT03822962 is currently terminated. Last updated 6 September 2023.

Last reviewed 2023-09-06 · How we verify

NCT03822962

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pain Management Following Sinus Surgery

Terminated EARLY_PHASE1 Last updated 6 September 2023

What this trial tests

EARLY_PHASE1 trial testing Ibuprofen 600Mg Tablet in Nasal Sinus; Inflammation in 10 participants. Terminated before completion.

Timeline

7 November 2020

Primary endpoint
30 May 2023

30 May 2023

Quick facts

Lead sponsor	University of Nebraska
Phase	EARLY_PHASE1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	7 November 2020
Primary completion	30 May 2023
Estimated completion	30 May 2023
Sites	2 locations across United States

Drugs / interventions tested

Ibuprofen 600Mg Tablet — full drug profile →
Standard Regimen | Tylenol

Conditions studied

Nasal Sinus; Inflammation — all drugs for Nasal Sinus; Inflammation →
Opioid Abuse — all drugs for Opioid Abuse →
Pain, Postoperative — all drugs for Pain, Postoperative →

Sponsor

University of Nebraska

Who can join

Adults 18 to 65, any sex, with Nasal Sinus; Inflammation or Opioid Abuse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Study evaluates the effect of adding Non-steroidal anti-inflammatories (NSAIDs) to the post-operative pain management of sinus surgery patients and wether or not this addition reduces or eliminates the need for narcotic pain medications. Patients will be instructed to take an NSAID regimen after surgery and will be instructed to take narcotics only for breakthrough pain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Nebraska trials

Trials by the same sponsor.

NCT07507006 — Feasibility Study of the Flash-Sole: A Wearable Midsole With Soft Actuators for Walking Assistance · NA · not yet recruiting
NCT07517705 — MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma · NA · not yet recruiting
NCT07506993 — Inflammation in Clear Aligners With and Without Attachments · not yet recruiting
NCT07207850 — Parents Helping Parents for Youth Vaping Cessation · NA · not yet recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03822962 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Nebraska
Last refreshed: 6 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03822962.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing